J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text PDF] （in Japanese / 1592KB） [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 90(9): 1459-1462, 1989

Report on the annual meeting

ADOPTIVE IMMUNOTHEAPY WITH LAK CELL AND IL2 AGAINST PRIMARY LUNG CANCER

Department of Surgery, Institute of Pulmoanry Cancer Research School of Medicine, Chiba University

Hideki Kimura, Yutaka Yamaguchi

Adoptive immunotheapy using LAK cells and IL-2 was performed against stage III and IV primary lung cancer patients after surgery. A randomized controlled study consisting of control group A, chemotherapy (CDDP+VDS) group B and chemo-immunotherapy (CDDP+VDS, IL2+LAK cells) group C suggested better survival rate in the group C.
Direct effects were studied against 8 recurrent or inoperable lung cancer cases. Complete response was obtained against a pleuritis and pericarditis carcinomatosa case when in vitro stimulated LAK cells (St-LAK) were administered locally. Partial response was observed against a inoperable case when LAK-BAI (bronchial arterial infusion) was combined with radiation therapy.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.